Revel-Vilk, Shoshana http://orcid.org/0000-0001-9151-0337
Shalev, Varda
Gill, Aidan
Paltiel, Ora
Manor, Orly
Tenenbaum, Avraham
Azani, Liat
Chodick, Gabriel
Funding for this research was provided by:
Takeda
Article History
Received: 28 July 2023
Accepted: 19 January 2024
First Online: 16 February 2024
Declarations
:
: The study design was approved by MHS Institutional Review Board (0013–21-ASMC). Patient consent was waived owing to the use of de-identified, anonymized data.
: Patient consent was waived owing to the use of de-identified, anonymized data.
: SRV has received research grants, speaker fees, and travel support from Pfizer, Sanofi Genzyme, and Takeda; VS is the chief marketing officer of Alike and has received speaker fees from Novartis and Roche; AG is a former employee and a stockholder of Takeda; LA and GC are employees of MaccabiTech; and OP, OM, and AT declare that they have no competing interests.